You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟川藥業(600566.SH)與恆翼生物醫藥簽署獨家合作協議
格隆匯 11-06 15:57

格隆匯11月6日丨濟川藥業(600566.SH)公佈,公司全資子公司濟川藥業集團有限公司與恆翼生物醫藥(上海)股份有限公司簽署獨家合作協議,約定在中國大陸地區(不包括香港特別行政區、澳門特別行政區和台灣地區)對恆翼生物擁有或控制的一種PDE4抑制劑醫藥產品以及組合產品(以下簡稱“目標產品1”)和一種蛋白酶抑制劑醫藥產品(包括其各種劑型)(以下簡稱“目標產品2”)約定的適應症進行合作。

濟川有限支付的首付款將不超過1.8億人民幣,開發里程碑付款將不超過1,212.5萬美元,銷售里程碑將不超過2,000萬美元,並與恆翼生物按照同等比例共同承擔目標產品1和2後續的研發費用,同時按照同等比例享受銷售利潤。

目標產品1是一種口服選擇性磷酸二酯酶4(PDE4)抑制劑,通過抑制機體細胞內環磷酸腺苷(cAMP)降解,升高細胞內的cAMP以調控促炎細胞因子水平從而抑制炎症反應,對於免疫和炎症領域相關疾病的治療,包括銀屑病、特應性皮炎及慢性阻塞性肺疾病等具有顯着的臨牀意義和價值。該產品具有對PDE4靶點特異選擇性和低中樞神經系統滲透性的特點和優勢,可以提供更好的耐受性和安全性;給藥方式為口服,患者的依從性和便利性良好。

目標產品2是一種蛋白酶抑制劑,對關鍵的消化酶具有抑制活性,如胰蛋白酶、胰凝乳蛋白酶、彈性蛋白酶和腸激酶以及其他消化酶。外科手術中對腸粘膜屏障的細微干擾經常發生,並引起從腸腔釋放消化酶,進而產生胃腸道功能障礙的病理作用。該產品通過抑制腸腔內的消化酶阻斷腸道粘膜屏障破壞的下游效應,從而改善腹腔手術後胃腸功能恢復、減少術後腸梗阻(POI)。

本次交易完成後,公司將進一步加強產品線的豐富程度,有利於公司業務的可持續發展,符合公司的發展戰略和長遠利益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account